HuoXue QianYang QuTan Recipe attenuates left ventricular hypertrophy in obese hypertensive rats by improving mitochondrial function through SIRT1/PGC-1α deacetylation pathway

Jing Wang, Zhenhua Dong, Mingtai Gui, Lei Yao, Jianhua Li, Xunjie Zhou, Deyu FuBioscience 2019 · DOI

TL;DR

This study investigates the traditional Chinese medicine formula, HuoXue QianYang QuTan Recipe (HQQR), for its potential to treat left ventricular hypertrophy (LVH) in obese hypertensive rats. The research demonstrates that HQQR effectively reduces body weight, blood pressure, and improves metabolic profiles, while crucially enhancing mitochondrial function via the SIRT1/PGC-1α pathway, thereby mitigating LVH.

What Problem Does This Paper Address?

Obesity and hypertension are significant risk factors for cardiovascular diseases, particularly left ventricular hypertrophy (LVH). LVH is a condition where the heart's main pumping chamber thickens, leading to impaired function and increasing the risk of heart failure. Mitochondrial dysfunction is increasingly recognized as a key contributor to the development and progression of LVH. While traditional Chinese medicine formulas like HuoXue QianYang QuTan Recipe (HQQR) are clinically used for obesity and hypertension, their precise mechanisms in addressing LVH, especially concerning mitochondrial health, remain unclear. This paper aims to elucidate these mechanisms by examining HQQR's impact on mitochondrial function and the SIRT1/PGC-1α pathway in a rat model of obesity-induced hypertension and LVH.

Methods

The study employed a rat model of obesity hypertension (OBH) induced by a high-fat diet (HFD) in spontaneously hypertensive rats (SHR). Rats were divided into five groups: a control group (WKY-ND), a hypertensive group (SHR-ND), an obese hypertensive group (OBH-HF), and two treatment groups receiving either valsartan (OBH-HF/V) or HQQR (OBH-HF/H).

Key measurements and analyses included:

  • Physiological parameters: Body weight, Lee index (an indicator of obesity), and blood pressure (systolic and diastolic) were monitored regularly.
  • Metabolic assessment: Glycolipid metabolism was evaluated by measuring serum levels of total cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, fasting blood glucose (FBG), and fasting insulin (FIN), from which the HOMA-IR index was calculated.
  • LVH assessment: Left ventricle mass index (LVMI) was determined, and histopathological examination (H&E and WGA staining) was performed to assess cardiac hypertrophy and cardiomyocyte size.
  • Mitochondrial function:
    • Mitochondrial ultrastructure was examined using transmission electron microscopy.
  • Mitochondrial oxidative stress was assessed by measuring Mn-SOD activity.
  • Myocardial ATP content was measured as an indicator of energy production.
  • Mitochondrial DNA (mtDNA) copy number was assessed using the ratio of COX1 to β-actin.
  • Molecular mechanisms:
    • Protein expression of key mitochondrial biogenesis regulators (SIRT1, PGC-1α, NRF1, TFAM) and electron transport chain subunits (COX1, ATPase6) was analyzed by Western blot.
  • PGC-1α acetylation was investigated using co-immunoprecipitation followed by Western blot.

Datasets

Not discussed in the paper. The study utilized an animal model and standard laboratory reagents.

Key Insights and Ideas

  • HQQR as a multi-faceted therapeutic: The study highlights HQQR's ability to address multiple facets of the obese hypertensive condition, not just blood pressure but also weight gain and metabolic dysregulation. This suggests a holistic approach to managing this complex comorbidity.
  • Mitochondrial health as a central target: The research strongly implicates mitochondrial dysfunction as a critical link between obesity, hypertension, and LVH. This reinforces the growing understanding of mitochondria's pivotal role in cardiovascular health.
  • SIRT1/PGC-1α pathway as a key mediator: The identification of the SIRT1/PGC-1α deacetylation pathway as a mechanism through which HQQR improves mitochondrial function is a significant finding. This pathway is crucial for regulating mitochondrial biogenesis and function, and its modulation by HQQR offers a specific molecular target.
  • Deacetylation of PGC-1α is critical: The observation that HQQR reduces PGC-1α acetylation in OBH rats is particularly important. PGC-1α is a master regulator of mitochondrial biogenesis, and its deacetylation by SIRT1 is known to enhance its activity. This finding directly links HQQR's action to improved mitochondrial capacity.

Key Results

  • Obesity and Hypertension Alleviation: HQQR treatment significantly reduced body weight, Lee index, systolic blood pressure (SBP), and diastolic blood pressure (DBP) in OBH rats compared to the untreated OBH-HF group. The antihypertensive effect was comparable to valsartan.
  • Metabolic Improvement: HQQR treatment improved glycolipid metabolism by reducing TC, TG, LDL-C, FBG, and HOMA-IR index, while increasing HDL-C levels.
  • LVH Mitigation: HQQR significantly decreased LVMI and reduced cardiomyocyte cross-sectional area, indicating a reduction in cardiac hypertrophy. It also normalized the expression of hypertrophic biomarkers ANP and β-MHC.
  • Mitochondrial Function Enhancement:
    • HQQR improved mitochondrial morphology and reduced oxidative stress damage (indicated by increased Mn-SOD activity).
  • It restored myocardial ATP content, suggesting improved energy production.
  • HQQR increased mtDNA copy number, indicating enhanced mitochondrial biogenesis.
  • Protein expression of key mitochondrial biogenesis regulators (SIRT1, PGC-1α, NRF1, TFAM) and ETC subunits (COX1, ATPase6) was upregulated by HQQR.
  • SIRT1/PGC-1α Pathway Modulation: HQQR treatment significantly reduced PGC-1α acetylation in OBH rats, suggesting activation of the SIRT1/PGC-1α deacetylation pathway.

Limitations and Future Work

  • Animal Model: While the rat model effectively mimics aspects of obesity-induced hypertension and LVH, it may not fully replicate the complexity of human disease.
  • Specific Compound Isolation: The study uses a complex herbal recipe (HQQR). Identifying the specific active compounds within HQQR responsible for these effects would be a valuable next step.
  • Long-term Effects: The study focused on a 10-week treatment period. Further research could explore the long-term efficacy and potential for sustained benefits.
  • Human Trials: Translating these findings to human clinical trials would be essential to confirm HQQR's therapeutic potential in patients.

The authors suggest that further investigation into the specific active components of HQQR and their precise molecular interactions could lead to more targeted therapeutic strategies for obesity-related cardiovascular diseases.

Summary updated

Abstract

Mitochondrial dysfunction plays a vital role in the progression of left ventricular hypertrophy (LVH). Previous studies have confirmed that the disorder of SIRT1/PGC-1α deacetylation pathway aggravated mitochondrial dysfunction. HuoXue QianYang QuTan Recipe (HQQR) is a commonly used prescription that has shown therapeutic effects on obesity hypertension and its complications. However, the potential mechanisms are still unclear. In the present study, obesity hypertension (OBH) was established in rats and we investigated the efficacy and mechanisms of HQQR on LVH. Rats were divided into the five groups: (1) WKY-ND group, (2) SHR-ND group, (3) OBH-HF group, (4) OBH-HF/V group and (5) OBH-HF/H group. We evaluated body weight, Lee index and blood pressure (BP) before and every 2 weeks after treatment. After 10 weeks of treatment, we mainly detected glycolipid metabolic index, the severity of LVH, mitochondrial function along with SIRT1/PGC-1α deacetylation pathway. Our results showed that HQQR significantly lowered body weight, Lee index, BP and improved the disorder of glycolipid metabolism in OBH rats. Importantly, we uncovered HQQR could alleviate mitochondrial dysfunction in OBH rats by regulating SIRT1/PGC-1α deacetylation pathway. These changes could be associated with the inhibition of LVH.
BibTeX
@inproceedings{wang2019huoxue,
  author = {Jing Wang and Zhenhua Dong and Mingtai Gui and Lei Yao and Jianhua Li and Xunjie Zhou and Deyu Fu},
  title = {{HuoXue QianYang QuTan Recipe attenuates left ventricular hypertrophy in obese hypertensive rats by improving mitochondrial function through SIRT1/PGC-1α deacetylation pathway}},
  booktitle = {Bioscience},
  year = {2019},
  doi = {10.1042/bsr20192909},
}
Figure